Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Analogue-based drug discovery [[electronic resource] /] / János Fischer, C. Robin Ganellin
| Analogue-based drug discovery [[electronic resource] /] / János Fischer, C. Robin Ganellin |
| Pubbl/distr/stampa | Weinheim ; ; [Chichester], : Wiley-VCH, c2006 |
| Descrizione fisica | 1 online resource (609 p.) |
| Disciplina | 615.19 |
| Altri autori (Persone) |
FischerJános
GanellinC. R (C. Robin) |
| Soggetto topico |
Drug development
Pharmacology |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-280-72276-2
9786610722761 3-527-60800-1 3-527-60749-8 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Analogue-based Drug Discovery; Contents; Preface; Introduction; List of Contributors; Abbreviations; Part I General Aspects of Analogue-Based Drug Discovery; 1 Analogues as a Means of Discovering New Drugs; 1.1 Designing of Analogues; 1.1.1 Analogues Produced by Homologous Variations; 1.1.1.1 Homology Through Monoalkylation; 1.1.1.2 Polymethylenic Bis-Ammonium Compounds: Hexa- and Decamethonium; 1.1.1.3 Homology in Cyclic Compounds; 1.1.2 Analogues Produced by Vinylogy; 1.1.2.1 Zaprinast Benzologues; 1.1.3 Analogues Produced by Isosteric Variations
1.1.3.1 The Dominant Parameter is Structural1.1.3.2 The Dominant Parameter is Electronic; 1.1.3.3 The Dominant Parameter is Lipophilicity; 1.1.4 Positional Isomers Produced as Analogues; 1.1.5 Optical Isomers Produced as Analogues; 1.1.5.1 Racemic Switches; 1.1.5.2 Specific Profile for Each Enantiomer; 1.1.6 Analogues Produced by Ring Transformations; 1.1.7 Twin Drugs; 1.2 The Pros and Cons of Analogue Design; 1.2.1 The Success is Almost Warranted; 1.2.2 The Information is Available; 1.2.3 Financial Considerations; 1.2.4 Emergence of New Properties 1.3 Analogue Design as a Means of Discovering New Drugs1.3.1 New Uses for Old Drugs; 1.3.2 The PASS Program; 1.3.3 New Leads from Old Drugs: The SOSA Approach; 1.3.3.1 Definition; 1.3.3.2 Rationale; 1.3.3.3 Availability; 1.3.3.4 Examples; 1.3.3.4 Discussion; 1.4 Conclusion; 2 Drug Likeness and Analogue-Based Drug Discovery; 3 Privileged Structures and Analogue-Based Drug Discovery; 3.1 Introduction; 3.2 Drugs from Side Effects; 3.3 Agonists and Antagonists; 3.4 Privileged Structures; 3.5 Drug Action on Target Classes; 3.5.1 GPCR Ligands; 3.5.2 Nuclear Receptor Ligands; 3.5.3 Integrin Ligands 3.5.4 Kinase Inhibitors3.5.5 Phosphodiesterase Inhibitors; 3.5.6 Neurotransmitter Uptake Inhibitors; 3.6 Summary and Conclusions; Part II Selected Examples of Analogue-Based Drug Discoveries; 1 Development of Anti-Ulcer H(2)-Receptor Histamine Antagonists; 1.1 Introduction; 1.2 The Prototype Drug, Burimamide, Defined Histamine H(2)-Receptors; 1.3 The Pioneer Drug, Cimetidine: A Breakthrough for Treating Peptic Ulcer Disease; 1.4 Ranitidine: The First Successful Analogue of H(2) Antagonists; 1.5 The Discovery of Tiotidine and Famotidine; 1.6 Other Compounds 1.7 The Use of H(2)-Receptor Histamine Antagonists as Medicines2 Esomeprazole in the Framework of Proton-Pump Inhibitor Development; 2.1 Towards Omeprazole: The First Proton-Pump Inhibitor; 2.2 The Treatment of Acid-Related Disorders Before Losec®; 2.3 Pioneer Research at Hässle during the 1960s and 1970s; 2.3.1 Toxicological Challenges; 2.3.2 Discovery of H(+), K(+)-ATPase: The Gastric Proton Pump; 2.3.3 Analogue Optimization; 2.4 The Development of Omeprazole; 2.4.1 Further Toxicological Challenges and the Halt of the Clinical Program; 2.4.2 Resumption of Clinical Studies 2.4.3 Omeprazole Reaches the Market and Supersedes H(2)-Receptor Antagonists |
| Record Nr. | UNINA-9910144274903321 |
| Weinheim ; ; [Chichester], : Wiley-VCH, c2006 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Analogue-based drug discovery / / Janos Fischer, C. Robin Ganellin
| Analogue-based drug discovery / / Janos Fischer, C. Robin Ganellin |
| Pubbl/distr/stampa | Weinheim ; ; [Chichester], : Wiley-VCH, c2006 |
| Descrizione fisica | 1 online resource (609 p.) |
| Disciplina | 615.19 |
| Altri autori (Persone) |
FischerJanos
GanellinC. R (C. Robin) |
| Soggetto topico |
Drug development
Pharmacology |
| ISBN |
1-280-72276-2
9786610722761 3-527-60800-1 3-527-60749-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Analogue-based Drug Discovery; Contents; Preface; Introduction; List of Contributors; Abbreviations; Part I General Aspects of Analogue-Based Drug Discovery; 1 Analogues as a Means of Discovering New Drugs; 1.1 Designing of Analogues; 1.1.1 Analogues Produced by Homologous Variations; 1.1.1.1 Homology Through Monoalkylation; 1.1.1.2 Polymethylenic Bis-Ammonium Compounds: Hexa- and Decamethonium; 1.1.1.3 Homology in Cyclic Compounds; 1.1.2 Analogues Produced by Vinylogy; 1.1.2.1 Zaprinast Benzologues; 1.1.3 Analogues Produced by Isosteric Variations
1.1.3.1 The Dominant Parameter is Structural1.1.3.2 The Dominant Parameter is Electronic; 1.1.3.3 The Dominant Parameter is Lipophilicity; 1.1.4 Positional Isomers Produced as Analogues; 1.1.5 Optical Isomers Produced as Analogues; 1.1.5.1 Racemic Switches; 1.1.5.2 Specific Profile for Each Enantiomer; 1.1.6 Analogues Produced by Ring Transformations; 1.1.7 Twin Drugs; 1.2 The Pros and Cons of Analogue Design; 1.2.1 The Success is Almost Warranted; 1.2.2 The Information is Available; 1.2.3 Financial Considerations; 1.2.4 Emergence of New Properties 1.3 Analogue Design as a Means of Discovering New Drugs1.3.1 New Uses for Old Drugs; 1.3.2 The PASS Program; 1.3.3 New Leads from Old Drugs: The SOSA Approach; 1.3.3.1 Definition; 1.3.3.2 Rationale; 1.3.3.3 Availability; 1.3.3.4 Examples; 1.3.3.4 Discussion; 1.4 Conclusion; 2 Drug Likeness and Analogue-Based Drug Discovery; 3 Privileged Structures and Analogue-Based Drug Discovery; 3.1 Introduction; 3.2 Drugs from Side Effects; 3.3 Agonists and Antagonists; 3.4 Privileged Structures; 3.5 Drug Action on Target Classes; 3.5.1 GPCR Ligands; 3.5.2 Nuclear Receptor Ligands; 3.5.3 Integrin Ligands 3.5.4 Kinase Inhibitors3.5.5 Phosphodiesterase Inhibitors; 3.5.6 Neurotransmitter Uptake Inhibitors; 3.6 Summary and Conclusions; Part II Selected Examples of Analogue-Based Drug Discoveries; 1 Development of Anti-Ulcer H(2)-Receptor Histamine Antagonists; 1.1 Introduction; 1.2 The Prototype Drug, Burimamide, Defined Histamine H(2)-Receptors; 1.3 The Pioneer Drug, Cimetidine: A Breakthrough for Treating Peptic Ulcer Disease; 1.4 Ranitidine: The First Successful Analogue of H(2) Antagonists; 1.5 The Discovery of Tiotidine and Famotidine; 1.6 Other Compounds 1.7 The Use of H(2)-Receptor Histamine Antagonists as Medicines2 Esomeprazole in the Framework of Proton-Pump Inhibitor Development; 2.1 Towards Omeprazole: The First Proton-Pump Inhibitor; 2.2 The Treatment of Acid-Related Disorders Before Losec®; 2.3 Pioneer Research at Hässle during the 1960s and 1970s; 2.3.1 Toxicological Challenges; 2.3.2 Discovery of H(+), K(+)-ATPase: The Gastric Proton Pump; 2.3.3 Analogue Optimization; 2.4 The Development of Omeprazole; 2.4.1 Further Toxicological Challenges and the Halt of the Clinical Program; 2.4.2 Resumption of Clinical Studies 2.4.3 Omeprazole Reaches the Market and Supersedes H(2)-Receptor Antagonists |
| Record Nr. | UNINA-9910877327603321 |
| Weinheim ; ; [Chichester], : Wiley-VCH, c2006 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Analogue-based drug discovery II [[electronic resource] /] / edited by Janos Fischer and C. Robin Ganellin
| Analogue-based drug discovery II [[electronic resource] /] / edited by Janos Fischer and C. Robin Ganellin |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2010 |
| Descrizione fisica | 1 online resource (566 p.) |
| Disciplina | 615.19 |
| Altri autori (Persone) |
FischerJános
GanellinC. R (C. Robin) |
| Soggetto topico |
Drug development
Drugs - Design |
| Soggetto genere / forma | Electronic books. |
| ISBN |
3-527-63212-3
1-282-78383-1 9786612783838 3-527-63003-1 3-527-63004-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Analogue-based Drug Discovery II; Contents; Preface; Introduction; Abbreviations; Part I: General Aspects; 1 Optimizing Drug Therapy by Analogues; 2 Standalone Drugs; 3 Application of Molecular Modeling in Analogue-Based Drug Discovery; 4 Issues for the Patenting of Analogues; Part II: Analogue Classes; 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes; 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction; 7 Rifamycins, Antibacterial Antibiotics and Their New Applications; 8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs
9 Anthracyclines, Optimizing Anticancer Analogues10 Paclitaxel and Epothilone Analogues, Anticancer Drugs; 11 Selective Serotonin Reuptake Inhibitors for the Treatment of Depression; 12 Muscarinic Receptor Antagonists in the Treatment of COPD; 13 ß-Adrenoceptor Agonists and Asthma; Part III: Case Histories; 14 Liraglutide, a GLP-1 Analogue to Treat Diabetes; 15 Eplerenone: Selective Aldosterone Antagonist; 16 Clevudine, to Treat Hepatitis B Viral Infection; 17 Rilpivirine, a Non-nucleoside Reverse Transcriptase Inhibitor to Treat HIV-1 18 Tipranavir, a Non-Peptidic Protease Inhibitor for Multi-drug Resistant HIV19 Lapatinib, an Anticancer Kinase Inhibitor; 20 Dasatinib, a Kinase Inhibitor to Treat Chronic Myelogenous Leukemia; 21 Venlafaxine and Desvenlafaxine, Selective Norepinephrine and Serotonin Reuptake Inhibitors to Treat Major Depressive Disorder; Index |
| Record Nr. | UNINA-9910140756503321 |
| Weinheim, : Wiley-VCH, c2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Analogue-based drug discovery II [[electronic resource] /] / edited by Janos Fischer and C. Robin Ganellin
| Analogue-based drug discovery II [[electronic resource] /] / edited by Janos Fischer and C. Robin Ganellin |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2010 |
| Descrizione fisica | 1 online resource (566 p.) |
| Disciplina | 615.19 |
| Altri autori (Persone) |
FischerJános
GanellinC. R (C. Robin) |
| Soggetto topico |
Drug development
Drugs - Design |
| ISBN |
3-527-63212-3
1-282-78383-1 9786612783838 3-527-63003-1 3-527-63004-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Analogue-based Drug Discovery II; Contents; Preface; Introduction; Abbreviations; Part I: General Aspects; 1 Optimizing Drug Therapy by Analogues; 2 Standalone Drugs; 3 Application of Molecular Modeling in Analogue-Based Drug Discovery; 4 Issues for the Patenting of Analogues; Part II: Analogue Classes; 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes; 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction; 7 Rifamycins, Antibacterial Antibiotics and Their New Applications; 8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs
9 Anthracyclines, Optimizing Anticancer Analogues10 Paclitaxel and Epothilone Analogues, Anticancer Drugs; 11 Selective Serotonin Reuptake Inhibitors for the Treatment of Depression; 12 Muscarinic Receptor Antagonists in the Treatment of COPD; 13 ß-Adrenoceptor Agonists and Asthma; Part III: Case Histories; 14 Liraglutide, a GLP-1 Analogue to Treat Diabetes; 15 Eplerenone: Selective Aldosterone Antagonist; 16 Clevudine, to Treat Hepatitis B Viral Infection; 17 Rilpivirine, a Non-nucleoside Reverse Transcriptase Inhibitor to Treat HIV-1 18 Tipranavir, a Non-Peptidic Protease Inhibitor for Multi-drug Resistant HIV19 Lapatinib, an Anticancer Kinase Inhibitor; 20 Dasatinib, a Kinase Inhibitor to Treat Chronic Myelogenous Leukemia; 21 Venlafaxine and Desvenlafaxine, Selective Norepinephrine and Serotonin Reuptake Inhibitors to Treat Major Depressive Disorder; Index |
| Record Nr. | UNINA-9910830524603321 |
| Weinheim, : Wiley-VCH, c2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Analogue-based drug discovery II / / edited by Janos Fischer and C. Robin Ganellin
| Analogue-based drug discovery II / / edited by Janos Fischer and C. Robin Ganellin |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2010 |
| Descrizione fisica | 1 online resource (566 p.) |
| Disciplina | 615.19 |
| Altri autori (Persone) |
FischerJanos
GanellinC. R (C. Robin) |
| Soggetto topico |
Drug development
Drugs - Design |
| ISBN |
3-527-63212-3
1-282-78383-1 9786612783838 3-527-63003-1 3-527-63004-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Analogue-based Drug Discovery II; Contents; Preface; Introduction; Abbreviations; Part I: General Aspects; 1 Optimizing Drug Therapy by Analogues; 2 Standalone Drugs; 3 Application of Molecular Modeling in Analogue-Based Drug Discovery; 4 Issues for the Patenting of Analogues; Part II: Analogue Classes; 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes; 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction; 7 Rifamycins, Antibacterial Antibiotics and Their New Applications; 8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs
9 Anthracyclines, Optimizing Anticancer Analogues10 Paclitaxel and Epothilone Analogues, Anticancer Drugs; 11 Selective Serotonin Reuptake Inhibitors for the Treatment of Depression; 12 Muscarinic Receptor Antagonists in the Treatment of COPD; 13 ß-Adrenoceptor Agonists and Asthma; Part III: Case Histories; 14 Liraglutide, a GLP-1 Analogue to Treat Diabetes; 15 Eplerenone: Selective Aldosterone Antagonist; 16 Clevudine, to Treat Hepatitis B Viral Infection; 17 Rilpivirine, a Non-nucleoside Reverse Transcriptase Inhibitor to Treat HIV-1 18 Tipranavir, a Non-Peptidic Protease Inhibitor for Multi-drug Resistant HIV19 Lapatinib, an Anticancer Kinase Inhibitor; 20 Dasatinib, a Kinase Inhibitor to Treat Chronic Myelogenous Leukemia; 21 Venlafaxine and Desvenlafaxine, Selective Norepinephrine and Serotonin Reuptake Inhibitors to Treat Major Depressive Disorder; Index |
| Record Nr. | UNINA-9910877334703321 |
| Weinheim, : Wiley-VCH, c2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Analogue-based drug discovery III [[electronic resource] /] / edited by János Fischer, C. Robin Ganellin and David P. Rotella
| Analogue-based drug discovery III [[electronic resource] /] / edited by János Fischer, C. Robin Ganellin and David P. Rotella |
| Pubbl/distr/stampa | Weinheim, Germany, : Wiley-VCH, 2013 |
| Descrizione fisica | 1 online resource (405 p.) |
| Disciplina | 615.19 |
| Altri autori (Persone) |
FischerJános
GanellinC. R (C. Robin) RotellaDavid P |
| Soggetto topico | Drug development |
| ISBN |
3-527-65108-X
1-299-24120-4 3-527-65111-X 3-527-65110-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | pt. 1. General aspects -- pt. 2. Drug classes -- pt. 3. Case studies. |
| Record Nr. | UNINA-9910141647903321 |
| Weinheim, Germany, : Wiley-VCH, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Analogue-based drug discovery III / / edited by János Fischer, C. Robin Ganellin and David P. Rotella
| Analogue-based drug discovery III / / edited by János Fischer, C. Robin Ganellin and David P. Rotella |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Weinheim, Germany, : Wiley-VCH, 2013 |
| Descrizione fisica | 1 online resource (405 p.) |
| Disciplina | 615.19 |
| Altri autori (Persone) |
FischerJános
GanellinC. R (C. Robin) RotellaDavid P |
| Soggetto topico | Drug development |
| ISBN |
3-527-65108-X
1-299-24120-4 3-527-65111-X 3-527-65110-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | pt. 1. General aspects -- pt. 2. Drug classes -- pt. 3. Case studies. |
| Record Nr. | UNINA-9910822629203321 |
| Weinheim, Germany, : Wiley-VCH, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Analysis of Safety Data of Drug Trials : An Update / / by Ton J. Cleophas, Aeilko H. Zwinderman
| Analysis of Safety Data of Drug Trials : An Update / / by Ton J. Cleophas, Aeilko H. Zwinderman |
| Autore | Cleophas Ton J |
| Edizione | [1st ed. 2019.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 |
| Descrizione fisica | 1 online resource (XI, 217 p. 191 illus., 28 illus. in color.) |
| Disciplina | 615.19 |
| Soggetto topico |
Medicine
Statistics Biomedicine, general Statistics and Computing/Statistics Programs |
| ISBN | 3-030-05804-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Preface -- General Introduction -- Significant and Insignificant Adverse Effect -- Incidence Ratios and Reporting Ratios of Adverse Effects -- Safety Analysis and the Alternative Hypothesis -- Forest Plots of Adverse Effects -- Graphics of Adverse Effects -- Repeated Measures Methods for Testing Adverse Effects -- Benefit Risk Ratios -- Equivalence, Non-inferiority and Superiority Testing of Adverse Effects -- Part II The Analysis of Dependent Adverse Effects -- Independent and Dependent Adverse Effects. Categorical Predictors Assessed as Dependent Adverse Effects. Adverse Effect of the Dependent Type in Crossover Trial -- Confoundings and Interactions Assessed as Dependent Adverse Effects -- Subgroup Characteristics Assessed as Dependent Adverse Effects -- Random Effects Assessed as Dependent Adverse Effects -- Outliers Assessed as Dependent Adverse Effects -- Index. . |
| Record Nr. | UNINA-9910337945403321 |
Cleophas Ton J
|
||
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Analytical chemistry : an introduction to pharmaceutical GMP laboratory / / Kim Huynh-Ba
| Analytical chemistry : an introduction to pharmaceutical GMP laboratory / / Kim Huynh-Ba |
| Autore | Huynh-Ba Kim |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : Wiley, , [2022] |
| Descrizione fisica | 1 online resource (419 pages) |
| Disciplina | 615.19 |
| Soggetto topico |
Pharmaceutical industry - Quality control
Analytical chemistry Drugs - Testing |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-119-68047-6
1-119-68046-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover -- Title Page -- Copyright Page -- Contents -- Einstein Quotation -- Preface -- About the Editor -- Biographies of Contributing Authors -- Editorial Notes -- Acknowledgments -- Chapter 1 Drug Regulations and the Pharmaceutical Laboratories -- 1.1 Introduction -- 1.2 Food and Drug Administration: Roles and Its Regulations -- 1.2.1 Code of Federation Regulations -- 1.2.2 FDA Guidance Documents -- 1.2.3 FDA Manual of Policies and Procedures -- 1.3 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and Its Role -- 1.3.1 ICH Background -- 1.3.2 ICH Structure -- 1.3.3 ICH Organization -- 1.3.4 ICH Topics -- 1.4 Pharmaceutical Analysis -- 1.4.1 Analytical Testing -- 1.4.2 Interaction of the Analytical Development Department and Other Functional Areas -- 1.4.3 Drug Development Process -- 1.5 Summary -- List of Abbreviations -- References -- Chapter 2 Good Manufacturing Practices (GMPs) and the Quality Systems -- 2.1 Introduction to Good Manufacturing Practices -- 2.2 Objectives of GMPs -- 2.2.1 Definitions -- 2.2.2 Organization of 21 CFR Regulations -- 2.3 Personnel Qualification and Responsibilities - Subpart B -- 2.3.1 Responsibilities of the Quality Control Unit -- 2.3.2 Personnel Qualifications and Responsibilities -- 2.4 Equipment - Subpart D -- 2.4.1 Metrology Functions -- 2.4.2 Qualification Phases -- 2.5 Laboratory Controls -- 2.5.1 General Requirements -- 2.5.2 Testing and Release for Distribution -- 2.5.3 Stability Program -- 2.5.4 Retention Program -- 2.6 Records and Reports -- 2.7 Pharmaceutical Quality -- 2.7.1 Quality Manual -- 2.7.2 Quality Risk Management -- 2.7.3 Product Quality Review -- 2.7.4 Pharmaceutical Quality Systems -- List of Abbreviations -- References -- Chapter 3 Analytical Techniques Used in the GMP Laboratory -- 3.1 Introduction -- 3.2 Definitions.
3.2.1 Raw Data and Analytical Data -- 3.2.2 Analyses -- 3.2.3 Analytical Documents -- 3.3 Basic Laboratory Procedures -- 3.3.1 Balances -- 3.3.2 Volumetric Glassware -- 3.3.3 Potentiometry (Ion-Selective Electrode) and pH Test -- 3.3.4 The Density Test -- 3.3.5 The Friability Test -- 3.3.6 The Hardness Test -- 3.3.7 The Titration Test -- 3.3.8 The Karl Fischer Titration-Water Determination -- 3.3.9 Loss on Drying -- 3.3.10 Residue on Ignition/Sulfated Ash -- 3.3.11 Thermo Gravimetric Analysis -- 3.3.12 Differential Scanning Calorimetry -- 3.3.13 The Disintegration Test -- 3.3.14 Particulate Matter -- 3.3.15 Osmolality -- 3.4 Chromatography -- 3.4.1 High-Performance Liquid Chromatography -- 3.4.2 Ultra-High-Pressure Liquid Chromatography -- 3.4.3 Detectors of Liquid Chromatography -- 3.4.4 System Suitability Tests for Chromatographic Methods -- 3.4.5 Maintenance of HPLC and UHPLC -- 3.4.6 Gas Chromatography -- 3.4.7 Thin-Layer Chromatography -- 3.4.8 Bio-Pharmaceutical Separations -- 3.5 Spectroscopic Sciences -- 3.5.1 Ultraviolet-Visible -- 3.5.2 Infrared-Absorption -- 3.5.3 Mass Spectroscopy -- 3.5.4 Atomic Absorption, Inductively Coupled Plasma, Inductively Coupled Plasma/Mass Spectrometry, and Inductively Coupled Plasma/Optical Emission Spectrometry -- 3.5.5 Nuclear Magnetic Resonance Spectroscopy -- 3.5.6 X-ray Absorption and X-ray Emission Spectrometry -- 3.6 Uniformity of Dosage Units -- 3.6.1 Weight Variation -- 3.6.2 Acceptance Criteria per USP < -- 905> -- -- 3.7 Elemental Analysis -- 3.8 Appearance -- 3.9 Visual Inspection -- 3.10 Microbiological Testing -- 3.10.1 Microbial Limits -- 3.10.2 Sterility -- 3.10.3 Bacterial Endotoxins -- 3.10.4 Antimicrobial Effectiveness Testing -- 3.11 Summary -- References -- Chapter 4 Control Strategies for Pharmaceutical Development -- 4.1 Introduction -- 4.2 Quality-by-Design Concept. 4.3 Risk Management -- 4.3.1 Risk Assessment -- 4.3.2 Risk Control -- 4.4 Establishing Specifications -- 4.4.1 What Is the Specification? -- 4.4.2 Typical Tests Included in the Specification of a Small Molecule Drug -- 4.4.3 Typical Tests Included in the Specification of Biological Drugs -- 4.4.4 Considerations of Setting Acceptance Criteria -- 4.5 Design of Experiments -- 4.5.1 Common Terms -- 4.5.2 Conducting the Study -- 4.5.3 Results Interpretation -- 4.5.4 Summary -- 4.6 Common Statistical Analysis -- 4.6.1 Mean, Standard Deviation (SD), and Relative Standard Deviation (RSD) -- 4.6.2 Confidence Interval -- 4.6.3 Statistical Significance (t-Test) -- 4.6.4 Outlier Detection -- 4.7 Summary -- List of Abbreviations -- References -- Chapter 5 Development and Validation of Analytical Procedures -- 5.1 Introduction -- 5.2 Method Development -- 5.2.1 Development of Physical, Chemical, and Microbiological Procedures -- 5.3 Qualification, Validation, and Verification -- 5.3.1 Qualification -- 5.3.2 Validation -- 5.3.3 Verification -- 5.3.4 Frequency of Study -- 5.4 Validation Parameters -- 5.4.1 Accuracy -- 5.4.2 Precision -- 5.4.3 Specificity -- 5.4.4 Quantitation and Detection Limits (QL and DL) -- 5.4.5 Linearity -- 5.4.6 Range -- 5.4.7 Robustness -- 5.4.8 System Suitability Tests (SST) -- 5.4.9 Stability of Samples During Analysis -- 5.4.10 Tie the Pieces Together -- 5.5 Validation for Physical, Chemical, Biotechnological, and Microbiological Procedures -- 5.6 Validation of In-process, Environmental, Release, and Stability Procedures -- 5.6.1 In-process Procedures -- 5.6.2 Environmental Procedures -- 5.6.3 Release and Stability Procedures -- 5.7 Other Procedures -- 5.7.1 Process Analytical Technology (PAT) -- 5.7.2 Parametric Release and Real-time Release -- 5.8 Validation of Procedures in Continuous and Batch Manufacturing -- 5.9 Summary. List of Abbreviations -- References -- Chapter 6 Transfer of Analytical Procedures -- 6.1 Introduction -- 6.2 Purpose of Method Transfer -- 6.3 Transfer Options -- 6.3.1 Method Transfer Plan -- 6.3.2 Comparative Testing -- 6.3.3 Co-validation -- 6.3.4 Extended Validation or Partial Validation -- 6.3.5 Transfer Waiver -- 6.4 Method Transfer Process -- 6.4.1 Preparation Phase -- 6.4.2 Gap Analysis -- 6.4.3 Method Training Phase -- 6.4.4 Method Qualification Phase -- 6.5 Transfer Protocol -- 6.5.1 Content of a Transfer Protocol -- 6.5.2 Objectives/Scope -- 6.5.3 Roles and Responsibilities -- 6.5.4 Assessment of Receiving Lab -- 6.5.5 Materials, Facilities, and Instrumentation -- 6.5.6 Analyst Training -- 6.5.7 Qualification Procedure -- 6.5.8 Acceptance Criteria -- 6.5.9 Protocol Amendment and Deviation -- 6.6 Method Transfer Report -- 6.6.1 Objectives -- 6.6.2 Data Evaluation -- 6.6.3 Conclusion of Transfer Report -- 6.6.4 Analytical Transfer File -- 6.7 Related Documents -- 6.8 Handling Transfer Failures -- 6.9 Transfer to a Contract Lab -- 6.10 Transfer to an International Site -- 6.11 Summary -- References -- Chapter 7 Dissolution Testing in the Pharmaceutical Laboratory -- 7.1 Introduction -- 7.2 Regulatory and Compendial Role in Dissolution Testing -- 7.3 Theory -- 7.4 Equipment Operation and Sources of Error -- 7.4.1 Equipment Variables -- 7.4.2 Media Deaeration -- 7.4.3 Vibration -- 7.4.4 Water Bath of Dissolution Equipment -- 7.4.5 Glass Vessels -- 7.5 Common Errors of Dissolution Apparatus -- 7.5.1 USP Apparatus 1 and 2 -- 7.5.2 USP Apparatus 3 -- 7.5.3 USP Apparatus 4 -- 7.5.4 USP Apparatus 5 -- 7.5.5 USP Apparatus 6 -- 7.5.6 USP Apparatus 7 -- 7.6 Dissolution Method Considerations -- 7.6.1 Sample Introduction -- 7.6.2 Media Attributes -- 7.6.3 Observations -- 7.6.4 Sinkers -- 7.6.5 Filters -- 7.6.6 Manual Sampling. 7.6.7 Automation of Dissolution Sampling -- 7.6.8 Cleaning of Dissolution Equipment -- 7.7 Method Development -- 7.7.1 Drug Properties -- 7.7.2 Dosage Form Properties -- 7.7.3 Dissolution Profile -- 7.7.4 Dissolution Media -- 7.7.5 Medium Volume -- 7.7.6 Deaeration -- 7.7.7 Speed -- 7.7.8 Sinkers -- 7.7.9 Filtration -- 7.7.10 Time Points - Immediate Release -- 7.7.11 Fast Stir or Infinity Point -- 7.7.12 Time Points for Extended-Release Products -- 7.8 Poorly Soluble Drugs -- 7.8.1 Sink Conditions -- 7.8.2 Apparatus Selection -- 7.8.3 The Discriminatory Power of the Method -- 7.9 Setting Specifications -- 7.10 Harmonization -- 7.11 Method Validation -- 7.12 Validation of Product Performance Parameters -- 7.12.1 Accuracy/Recovery -- 7.12.2 Selectivity -- 7.12.3 Solution Stability -- 7.12.4 Filter -- 7.12.5 Robustness -- 7.12.6 Intermediate Precision -- 7.12.7 Automated Methodology -- 7.13 Validation of the Analytical Finish -- 7.14 Method Transfer Considerations -- 7.14.1 Robustness -- 7.14.2 Details of the Analytical Method -- 7.14.3 Other Considerations -- 7.15 Good Manufacturing Practices (GMP) in the Dissolution Testing Laboratory -- 7.15.1 Metrology -- 7.15.2 Notebook Documentation -- 7.15.3 Equipment Qualification, Validation, and Method Critical Factors -- 7.15.4 Good Manufacturing Practice Audits -- 7.15.5 Training -- 7.16 Summary -- Acknowledgment -- List of Abbreviations -- Chapter 8 Analytical Data and the Documentation System -- 8.1 Introduction -- 8.1.1 Types of Documents -- 8.2 GMP for Records and Reports-Subpart J -- 8.2.1 General Requirements -- 8.2.2 Equipment Cleaning and Use Log -- 8.2.3 Component, Drug Product Container, Closure, and Labeling Records -- 8.2.4 Master Production and Control Records -- 8.2.5 Batch Production and Control Records -- 8.2.6 Production Record Review -- 8.2.7 Laboratory Records -- 8.3 Keeping Good Records. 8.3.1 Writing Good Procedures. |
| Record Nr. | UNINA-9910566699803321 |
|
Huynh-Ba Kim
|
||
| Hoboken, New Jersey : , : Wiley, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Analytical chemistry : an introduction to pharmaceutical GMP laboratory / / Kim Huynh-Ba
| Analytical chemistry : an introduction to pharmaceutical GMP laboratory / / Kim Huynh-Ba |
| Autore | Huynh-Ba Kim |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : Wiley, , [2022] |
| Descrizione fisica | 1 online resource (419 pages) |
| Disciplina | 615.19 |
| Soggetto topico |
Pharmaceutical industry - Quality control
Analytical chemistry Drugs - Testing |
| ISBN |
1-119-68047-6
1-119-68046-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover -- Title Page -- Copyright Page -- Contents -- Einstein Quotation -- Preface -- About the Editor -- Biographies of Contributing Authors -- Editorial Notes -- Acknowledgments -- Chapter 1 Drug Regulations and the Pharmaceutical Laboratories -- 1.1 Introduction -- 1.2 Food and Drug Administration: Roles and Its Regulations -- 1.2.1 Code of Federation Regulations -- 1.2.2 FDA Guidance Documents -- 1.2.3 FDA Manual of Policies and Procedures -- 1.3 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and Its Role -- 1.3.1 ICH Background -- 1.3.2 ICH Structure -- 1.3.3 ICH Organization -- 1.3.4 ICH Topics -- 1.4 Pharmaceutical Analysis -- 1.4.1 Analytical Testing -- 1.4.2 Interaction of the Analytical Development Department and Other Functional Areas -- 1.4.3 Drug Development Process -- 1.5 Summary -- List of Abbreviations -- References -- Chapter 2 Good Manufacturing Practices (GMPs) and the Quality Systems -- 2.1 Introduction to Good Manufacturing Practices -- 2.2 Objectives of GMPs -- 2.2.1 Definitions -- 2.2.2 Organization of 21 CFR Regulations -- 2.3 Personnel Qualification and Responsibilities - Subpart B -- 2.3.1 Responsibilities of the Quality Control Unit -- 2.3.2 Personnel Qualifications and Responsibilities -- 2.4 Equipment - Subpart D -- 2.4.1 Metrology Functions -- 2.4.2 Qualification Phases -- 2.5 Laboratory Controls -- 2.5.1 General Requirements -- 2.5.2 Testing and Release for Distribution -- 2.5.3 Stability Program -- 2.5.4 Retention Program -- 2.6 Records and Reports -- 2.7 Pharmaceutical Quality -- 2.7.1 Quality Manual -- 2.7.2 Quality Risk Management -- 2.7.3 Product Quality Review -- 2.7.4 Pharmaceutical Quality Systems -- List of Abbreviations -- References -- Chapter 3 Analytical Techniques Used in the GMP Laboratory -- 3.1 Introduction -- 3.2 Definitions.
3.2.1 Raw Data and Analytical Data -- 3.2.2 Analyses -- 3.2.3 Analytical Documents -- 3.3 Basic Laboratory Procedures -- 3.3.1 Balances -- 3.3.2 Volumetric Glassware -- 3.3.3 Potentiometry (Ion-Selective Electrode) and pH Test -- 3.3.4 The Density Test -- 3.3.5 The Friability Test -- 3.3.6 The Hardness Test -- 3.3.7 The Titration Test -- 3.3.8 The Karl Fischer Titration-Water Determination -- 3.3.9 Loss on Drying -- 3.3.10 Residue on Ignition/Sulfated Ash -- 3.3.11 Thermo Gravimetric Analysis -- 3.3.12 Differential Scanning Calorimetry -- 3.3.13 The Disintegration Test -- 3.3.14 Particulate Matter -- 3.3.15 Osmolality -- 3.4 Chromatography -- 3.4.1 High-Performance Liquid Chromatography -- 3.4.2 Ultra-High-Pressure Liquid Chromatography -- 3.4.3 Detectors of Liquid Chromatography -- 3.4.4 System Suitability Tests for Chromatographic Methods -- 3.4.5 Maintenance of HPLC and UHPLC -- 3.4.6 Gas Chromatography -- 3.4.7 Thin-Layer Chromatography -- 3.4.8 Bio-Pharmaceutical Separations -- 3.5 Spectroscopic Sciences -- 3.5.1 Ultraviolet-Visible -- 3.5.2 Infrared-Absorption -- 3.5.3 Mass Spectroscopy -- 3.5.4 Atomic Absorption, Inductively Coupled Plasma, Inductively Coupled Plasma/Mass Spectrometry, and Inductively Coupled Plasma/Optical Emission Spectrometry -- 3.5.5 Nuclear Magnetic Resonance Spectroscopy -- 3.5.6 X-ray Absorption and X-ray Emission Spectrometry -- 3.6 Uniformity of Dosage Units -- 3.6.1 Weight Variation -- 3.6.2 Acceptance Criteria per USP < -- 905> -- -- 3.7 Elemental Analysis -- 3.8 Appearance -- 3.9 Visual Inspection -- 3.10 Microbiological Testing -- 3.10.1 Microbial Limits -- 3.10.2 Sterility -- 3.10.3 Bacterial Endotoxins -- 3.10.4 Antimicrobial Effectiveness Testing -- 3.11 Summary -- References -- Chapter 4 Control Strategies for Pharmaceutical Development -- 4.1 Introduction -- 4.2 Quality-by-Design Concept. 4.3 Risk Management -- 4.3.1 Risk Assessment -- 4.3.2 Risk Control -- 4.4 Establishing Specifications -- 4.4.1 What Is the Specification? -- 4.4.2 Typical Tests Included in the Specification of a Small Molecule Drug -- 4.4.3 Typical Tests Included in the Specification of Biological Drugs -- 4.4.4 Considerations of Setting Acceptance Criteria -- 4.5 Design of Experiments -- 4.5.1 Common Terms -- 4.5.2 Conducting the Study -- 4.5.3 Results Interpretation -- 4.5.4 Summary -- 4.6 Common Statistical Analysis -- 4.6.1 Mean, Standard Deviation (SD), and Relative Standard Deviation (RSD) -- 4.6.2 Confidence Interval -- 4.6.3 Statistical Significance (t-Test) -- 4.6.4 Outlier Detection -- 4.7 Summary -- List of Abbreviations -- References -- Chapter 5 Development and Validation of Analytical Procedures -- 5.1 Introduction -- 5.2 Method Development -- 5.2.1 Development of Physical, Chemical, and Microbiological Procedures -- 5.3 Qualification, Validation, and Verification -- 5.3.1 Qualification -- 5.3.2 Validation -- 5.3.3 Verification -- 5.3.4 Frequency of Study -- 5.4 Validation Parameters -- 5.4.1 Accuracy -- 5.4.2 Precision -- 5.4.3 Specificity -- 5.4.4 Quantitation and Detection Limits (QL and DL) -- 5.4.5 Linearity -- 5.4.6 Range -- 5.4.7 Robustness -- 5.4.8 System Suitability Tests (SST) -- 5.4.9 Stability of Samples During Analysis -- 5.4.10 Tie the Pieces Together -- 5.5 Validation for Physical, Chemical, Biotechnological, and Microbiological Procedures -- 5.6 Validation of In-process, Environmental, Release, and Stability Procedures -- 5.6.1 In-process Procedures -- 5.6.2 Environmental Procedures -- 5.6.3 Release and Stability Procedures -- 5.7 Other Procedures -- 5.7.1 Process Analytical Technology (PAT) -- 5.7.2 Parametric Release and Real-time Release -- 5.8 Validation of Procedures in Continuous and Batch Manufacturing -- 5.9 Summary. List of Abbreviations -- References -- Chapter 6 Transfer of Analytical Procedures -- 6.1 Introduction -- 6.2 Purpose of Method Transfer -- 6.3 Transfer Options -- 6.3.1 Method Transfer Plan -- 6.3.2 Comparative Testing -- 6.3.3 Co-validation -- 6.3.4 Extended Validation or Partial Validation -- 6.3.5 Transfer Waiver -- 6.4 Method Transfer Process -- 6.4.1 Preparation Phase -- 6.4.2 Gap Analysis -- 6.4.3 Method Training Phase -- 6.4.4 Method Qualification Phase -- 6.5 Transfer Protocol -- 6.5.1 Content of a Transfer Protocol -- 6.5.2 Objectives/Scope -- 6.5.3 Roles and Responsibilities -- 6.5.4 Assessment of Receiving Lab -- 6.5.5 Materials, Facilities, and Instrumentation -- 6.5.6 Analyst Training -- 6.5.7 Qualification Procedure -- 6.5.8 Acceptance Criteria -- 6.5.9 Protocol Amendment and Deviation -- 6.6 Method Transfer Report -- 6.6.1 Objectives -- 6.6.2 Data Evaluation -- 6.6.3 Conclusion of Transfer Report -- 6.6.4 Analytical Transfer File -- 6.7 Related Documents -- 6.8 Handling Transfer Failures -- 6.9 Transfer to a Contract Lab -- 6.10 Transfer to an International Site -- 6.11 Summary -- References -- Chapter 7 Dissolution Testing in the Pharmaceutical Laboratory -- 7.1 Introduction -- 7.2 Regulatory and Compendial Role in Dissolution Testing -- 7.3 Theory -- 7.4 Equipment Operation and Sources of Error -- 7.4.1 Equipment Variables -- 7.4.2 Media Deaeration -- 7.4.3 Vibration -- 7.4.4 Water Bath of Dissolution Equipment -- 7.4.5 Glass Vessels -- 7.5 Common Errors of Dissolution Apparatus -- 7.5.1 USP Apparatus 1 and 2 -- 7.5.2 USP Apparatus 3 -- 7.5.3 USP Apparatus 4 -- 7.5.4 USP Apparatus 5 -- 7.5.5 USP Apparatus 6 -- 7.5.6 USP Apparatus 7 -- 7.6 Dissolution Method Considerations -- 7.6.1 Sample Introduction -- 7.6.2 Media Attributes -- 7.6.3 Observations -- 7.6.4 Sinkers -- 7.6.5 Filters -- 7.6.6 Manual Sampling. 7.6.7 Automation of Dissolution Sampling -- 7.6.8 Cleaning of Dissolution Equipment -- 7.7 Method Development -- 7.7.1 Drug Properties -- 7.7.2 Dosage Form Properties -- 7.7.3 Dissolution Profile -- 7.7.4 Dissolution Media -- 7.7.5 Medium Volume -- 7.7.6 Deaeration -- 7.7.7 Speed -- 7.7.8 Sinkers -- 7.7.9 Filtration -- 7.7.10 Time Points - Immediate Release -- 7.7.11 Fast Stir or Infinity Point -- 7.7.12 Time Points for Extended-Release Products -- 7.8 Poorly Soluble Drugs -- 7.8.1 Sink Conditions -- 7.8.2 Apparatus Selection -- 7.8.3 The Discriminatory Power of the Method -- 7.9 Setting Specifications -- 7.10 Harmonization -- 7.11 Method Validation -- 7.12 Validation of Product Performance Parameters -- 7.12.1 Accuracy/Recovery -- 7.12.2 Selectivity -- 7.12.3 Solution Stability -- 7.12.4 Filter -- 7.12.5 Robustness -- 7.12.6 Intermediate Precision -- 7.12.7 Automated Methodology -- 7.13 Validation of the Analytical Finish -- 7.14 Method Transfer Considerations -- 7.14.1 Robustness -- 7.14.2 Details of the Analytical Method -- 7.14.3 Other Considerations -- 7.15 Good Manufacturing Practices (GMP) in the Dissolution Testing Laboratory -- 7.15.1 Metrology -- 7.15.2 Notebook Documentation -- 7.15.3 Equipment Qualification, Validation, and Method Critical Factors -- 7.15.4 Good Manufacturing Practice Audits -- 7.15.5 Training -- 7.16 Summary -- Acknowledgment -- List of Abbreviations -- Chapter 8 Analytical Data and the Documentation System -- 8.1 Introduction -- 8.1.1 Types of Documents -- 8.2 GMP for Records and Reports-Subpart J -- 8.2.1 General Requirements -- 8.2.2 Equipment Cleaning and Use Log -- 8.2.3 Component, Drug Product Container, Closure, and Labeling Records -- 8.2.4 Master Production and Control Records -- 8.2.5 Batch Production and Control Records -- 8.2.6 Production Record Review -- 8.2.7 Laboratory Records -- 8.3 Keeping Good Records. 8.3.1 Writing Good Procedures. |
| Record Nr. | UNINA-9910830995003321 |
|
Huynh-Ba Kim
|
||
| Hoboken, New Jersey : , : Wiley, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
